Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for ...

Andrew Yee, MD, introduces the discussion by reviewing treatment challenges, patient education, and decision-making in ...

The company plans to announce Phase 1b interim data by mid-2026, and the TENACITY-01 study is expected to be completed by late 2028. This timing enables progression to Phase 2 evaluation following ...

The best PFS results we’ve ever seen in relapsed, refractory myeloma.”The combination of teclistamab (Tecvayli, Janssen) plus daratumumab (Darzalex, Johnson & Johnson/Janssen) reduced the risk for ...

In a 2024 review, Richardson and colleagues noted that the immunomodulatory drugs thalidomide, lenalidomide (Revlimid), and ...

Please provide your email address to receive an email when new articles are posted on . It is a truism that, “If you operate, you will have complications.” Wise surgeons plan ahead to avoid ...

The FDA approved epcoritamab plus R 2 on November 18 for the treatment of patients with relapsed or refractory FL. It also ...

In this study, researchers aimed to determine whether patients with standard-risk relapsed/refractory multiple myeloma had improved survival with earlier-line cilta-cel therapy.

Cancer Research UK's Centre for Drug Development is sponsoring and conducting the phase I/II clinical trial of ALETA-001, the lead agent in Aleta Biotherapeutics' portfolio. Additional clinical trial ...

Refractory angina is an increasingly prevalent clinical syndrome characterized by ongoing ischaemic symptoms despite optimal medical management in patients for whom traditional revascularization is ...

Safety and efficacy data from a phase 1 multicenter study evaluating rapcabtagene autoleucel, an investigational next-generation CD19-directed CAR-T cell therapy that is manufactured in 48 hours using ...

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the publication of clinical results from the ovarian cancer cohort of its Phase 1b C-800-01 trial evaluating ...